Sutro Biopharma

Yahoo Finance • 2 months ago

Sutro Biopharma GAAP EPS of -$0.14, revenue of $63.7M

* Sutro Biopharma press release [https://seekingalpha.com/pr/20194321-sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highlights] (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$0.14. *... Full story

Yahoo Finance • 2 months ago

Sutro Biopharma Inc (NASDAQ:STRO) Reports Q2 2025 Revenue Beat and Narrower Losses, Shares Rise in After-Hours Trading

SUTRO BIOPHARMA INC (NASDAQ:STRO [https://www.chartmill.com/stock/quote/STRO]) reported its second-quarter 2025 financial results, delivering a significant revenue beat while narrowing its losses compared to analyst expectations. The compa... Full story

Yahoo Finance • 2 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research... Full story

Yahoo Finance • 3 months ago

Earnings call transcript: Strongpoint Q2 2025 sees positive EBITDA, 18% revenue growth

Strongpoint ASA reported strong financial results for the second quarter of 2025, showcasing significant improvements in revenue and profitability. The company achieved an 18% year-over-year revenue increase, reaching NOK 350 million. EBIT... Full story

Yahoo Finance • 3 months ago

StrongPoint Q2 2025 slides: Revenue up 18%, EBITDA improves amid retail tech expansion

Introduction & Market Context StrongPoint ASA (OB:STRO) presented its second quarter 2025 results on July 11, showing continued revenue growth and improved profitability as the retail technology provider expands its footprint across Europ... Full story

Yahoo Finance • 3 months ago

Piper Sandler upgrades Sutro Biopharma stock rating on pipeline progress

Piper Sandler upgraded Sutro Biopharma (NASDAQ:STRO) from Neutral to Overweight on Monday, setting a price target of $2.00 for the biopharmaceutical company focused on antibody-drug conjugates (ADCs). According to InvestingPro data, the... Full story

Yahoo Finance • 6 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced e... Full story

Yahoo Finance • 6 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of Dec... Full story

Yahoo Finance • 6 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next... Full story

Yahoo Finance • 7 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), tod... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Sutro Biopharma, Inc. SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug co... Full story

Yahoo Finance • 2 years ago

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcy... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), toda... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates

Sutro Biopharma Inc (NASDAQ:STRO) released its 8-K filing on November 13, 2023, detailing third-quarter financials and recent business highlights. The company reported a cash and investment balance of $321.1 million, projecting a cash runw... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 - - Luvelta demonstrated encouraging prelim... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sutro Biopharma, Inc. (NASDAQ: STRO) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sutro Biopharma, Inc. (NASDAQ: STRO) (“Sutro”) on behalf of the company’s investors. Since January 2023, shares of Sutro’s common stock... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Sutro Biopharma, Inc.; Urges Sutro Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Sutro Biopharma, Inc. (Nasdaq: STRO) (“Sutro” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Su... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

- Luvelta demonstratedencouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα expression – - Safety profile was consist... Full story

Yahoo Finance • 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), toda... Full story

Yahoo Finance • 2 years ago

15 Best U.S. Stocks to Buy Now Under $10

In this article, we will discuss the 15 best U.S. stocks to buy now under $10. If you want to explore similar stocks, you can also take a look at 5 Best U.S. Stocks to Buy Now Under $10. The U.S. has always been a financial and economic h... Full story